• 

  December 15, 2025

  Revalia Bio Secures ~$30M Government Contract to Build the Future of Human-First Drug Development

  R.D. Solorzano

• 

  December 11, 2025

  Inside Curi Bio’s Human Tissue Platforms: How They Work, What the $10M Series B Will Accelerate, and Why It Matters

  R.D. Solorzano

• 

  November 20, 2025

  InSphero Acquires Doppl SA, Expanding Its 3D Cell Culture Portfolio with the Gri3D® Platform

  R.D. Solorzano

• 

  October 13, 2025

  L’Oréal and AMKbiotech Partner to Unlock Next-Generation Insights in Skin Biology with High-Plex Imaging

  R.D. Solorzano

• 

  October 3, 2025

  NIH Launches Nation’s First Dedicated Organoid Development Center

  R.D. Solorzano

• 

  September 23, 2025

  Prellis Biologics and Eli Lilly Sign Multi-Target Antibody Discovery Agreement

  R.D. Solorzano

• 

  May 6, 2025

  Quris Technologies Demonstrates Liver-Driven Brain Toxicity in New Multi-Organ Model

  R.D. Solorzano

• 

  May 6, 2025

  VivoSim Labs Introduces NAMkind Platform for Human-Based Drug Testing Models

  R.D. Solorzano

• 

  April 27, 2025

  Vivodyne CEO Discusses FDA’s Move Away from Animal Testing and the Future of Humanized Drug Development

  R.D. Solorzano

• 

  April 3, 2025

  Organovo Sells FXR Drug Program to Eli Lilly in Strategic Deal to Advance IBD Therapies

  R.D. Solorzano